Les infections d'hépatite C chez les jeunes usagers de drogues injectables: réponse à une tendance émergente

Le Plan d'Action pour la prévention, les soins et le traitement de l'hépatite virale vise à sonner l’alarme au sujet des taux rapides de transmission de l’hépatite C chez les usagers de drogues injectables et à y apporter une solution. Pour en savoir plus, en anglais, veuillez lire les informations ci-dessous.

Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.

In recent years, there has been an emerging epidemic of hepatitis C virus (HCV) infection among young injection drug users (IDU) in rural and suburban settings. Early this spring, the U.S. Department of Health and Human Services convened a multidisciplinary technical consultation to discuss the existing evidence and to identify and define priorities for the development of a public health response.

Already working together to implement the Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis—which includes among its priorities “reducing viral hepatitis caused by drug use behaviors”—the Office of HIV/AIDS and Infectious Disease Policy, the National Institutes of Health, the Centers for Disease Control and Prevention, the Substance Abuse and Mental Health Services Administration organized the consultation which brought together representatives of federal agencies, state health department officials, researchers, care providers, staff of community-based organizations, and other experts in the field.

Injection drug use is known to play a major role in HCV transmission. Surveillance data shared by Massachusetts in 2010 put a spotlight on an emerging HCV infection trend among young PWID.

Read here the full publication.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.